North China pharmaceutical group R&D co., ltd

Huayao Group Company has a strong independent research and development capability. 1970 the original central laboratory was expanded and reorganized into an antibiotic research institute, devoted to the research and development of new antibiotics, and successively took the lead in developing more than ten kinds of products in China, such as bacitracin, kasugamycin, pingyangmycin, amphotericin B, lincomycin, clindamycin phosphate and norvancomycin. 199 1 year, the antibiotic research institute was reorganized into a new drug research and development center, becoming the first enterprise technology center recognized by the state in the pharmaceutical industry. The new drug center has more than 200 excellent R&D personnel, equipped with advanced experimental instruments and a complete pilot system, making the development and achievements of new drugs a systematic project. Due to long-term high-intensity investment, new products are put on the market every year. At the same time of independent research and development, Huayao has carried out close cooperation with many scientific research institutions at home and abroad, attracting all kinds of scientific and technological resources to gather in enterprises and carrying out joint innovation in Industry-University-Research.

The development of new Chinese medicine is shifting from imitation to creation. Since the mid-1980s, we have gradually introduced and learned advanced platform technology for developing innovative drugs, and gradually formed our own innovative drug development system through cooperation with scientific research institutions, focusing on the screening of natural drugs and small molecular drugs, combinatorial chemistry technology and modern biotechnology.

1997, Huayao was recognized as a pilot enterprise of technological innovation by the State Economic and Trade Commission, and received strong support in research and development. In 2000, Huayao was recognized by the Ministry of Science and Technology as the industrialization base of the achievements of the 863 high-tech research and development plan.

Scientific and technological progress is the driving force for the development of North China Pharmaceutical Group.

The technology development department, new drug development center, environmental protection technology research institute, planning and design institute and engineering department of North China Pharmaceutical Group are all engaged in product development and industrialization.

North China Pharmaceutical Group has a high-level scientific research team, advanced scientific research and development equipment and strong new product development and pilot test capabilities.

By the end of 1999, Huabei Pharmaceutical Group had won 5 national invention awards. National Science and Technology Progress Award 18, and 70 provincial (ministerial) science and technology progress awards.

During the Eighth Five-Year Plan period, North China Pharmaceutical Group put into production more than 30 new products and varieties, and the output value of new products, varieties and specifications reached 900 million yuan in 1999.

North China Pharmaceutical Group Corporation is the first batch of technological innovation pilot enterprises of the State Economic and Trade Commission, and the new drug development center of North China Pharmaceutical Group is the first batch of enterprise technology centers recognized at the national level in China. The center has undertaken 13 new product research and two major process research projects, and has completed two new product research, obtained four new drug approval numbers, and six new drugs have entered the pilot stage.

After 2000, 1-2 innovative drugs or modern biotechnology drugs will be put on the market every year.